Archive · 21 Jul 2026
Indian Stock Market Midday Movers: Karur Vysya, CMPDI, Emcure, UltraTech, Paytm
On July 21, the Indian stock market was mixed.
Some stocks like Karur Vysya Bank and CMPDI went up because they made more money than last year.
Emcure Pharmaceuticals got approval for a new medicine, and UltraTech Cement sold more cement.
Paytm did well but its stock went down a little.
Pharma stocks did better than the rest of the market.
Karur Vysya Bank's stock surged over 11% due to strong Q2 earnings.
CMPDI's stock climbed over 7% with a 53.8% increase in net profit.
Emcure Pharmaceuticals' stock rose 2% after approval for Poviztra in MASH treatment.
UltraTech Cement's stock gained nearly 2% with a 17% increase in net profit.
Paytm's stock traded marginally lower despite a 28% increase in revenue.
- Who
- Investors and market analysts
- What
- Stock market performance and earnings reports
- When
- July 21, midday
- Where
- Indian stock market
- Why
- Strong quarterly earnings and sector-specific performance
Positive Market Sentiment
Negative Market Sentiment
Stock Performance
Positive Market Sentiment
Stocks like Karur Vysya Bank, CMPDI, Emcure Pharmaceuticals, and UltraTech Cement showed significant gains due to strong quarterly earnings and positive news.
Negative Market Sentiment
Paytm's stock traded marginally lower despite strong earnings, indicating mixed market sentiment.
Sector Performance
Positive Market Sentiment
Pharma stocks outperformed the broader market, with the Nifty Pharma index advancing around 1.8%.
Negative Market Sentiment
The broader market remained under pressure due to weakness in heavyweight financial stocks.
- Karur Vysya Bank
- Net profit up 45% YoY to Rs 755.70 crore, interest income up 19% to Rs 3,049.42 crore
- CMPDI
- Net profit up 53.8% YoY to Rs 116.27 crore, revenue up 17.6% to Rs 481.37 crore
- Emcure Pharmaceuticals
- Poviztra approved for MASH treatment
- UltraTech Cement
- Net profit up 17% YoY to Rs 2,599 crore, revenue up 16% to Rs 24,648 crore
- Paytm
- Revenue up 28% YoY to Rs 2,448 crore, EBITDA up 182% to Rs 203 crore
- Nifty Pharma Index
- Advanced around 1.8%